RTP Mobile Logo
Visiting Professors: Clinical Investigators Provide Their Perspectives on Current Cases and Emerging Research in the Management of Breast Cancer
Released January 2015

Proceedings from an ESMO 2014 Industry Satellite Symposium. Featuring perspectives from Drs Javier Cortes, John Crown, Angelo Di Leo and Hope S Rugo. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical, radiation and surgical oncologists and other healthcare professionals involved in the treatment of breast cancer.

    OVERVIEW OF ACTIVITY
    Each year nearly 1.4 million women are newly diagnosed with breast cancer, making it the most prevalent diagnosis among women and the second most common cancer in both sexes worldwide. Equally relevant, more than 450,000 patients will die due to this disease. As such, breast cancer has a tremendous global impact and has become the subject of extensive ongoing clinical research. For this reason, the clinical management of breast cancer is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets of relevance to the continuous delivery of quality care.

    By providing access to the latest research developments and expert perspectives, these proceedings from an international case-based CME symposium held at the 2014 ESMO Annual Meeting in Madrid, Spain aim to assist medical oncologists, breast surgeons and other healthcare providers as they attempt to formulate optimal disease management strategies in the face of a constantly evolving body of knowledge.

    LEARNING OBJECTIVES

    • Appropriately use existing and emerging biomarkers to assess risk and individualize therapy for patients with invasive early breast cancer.
    • Develop an evidence-based algorithm for the initial and long-term treatment of localized hormone receptor-positive pre- and postmenopausal breast cancer.
    • Individualize the selection of evidence-based adjuvant trastuzumab regimens for patients with HER2-overexpressing breast cancer.
    • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, incorporating existing, recently approved and investigational targeted treatments.
    • Formulate individualized approaches to neoadjuvant therapy for patients with ER-positive, HER2-negative disease and those with advanced triple-negative breast cancer.
    • Develop an evidence-based approach to clinical decision-making for patients with discordant assay results for ER or HER2.
    • Counsel appropriately selected patients about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. The participant should watch the video.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Javier Cortes, MD, PhD
    Head, Breast Cancer Program
    Vall d’Hebron University Hospital
    Vall d’Hebron Institute of Oncology
    Barcelona, Spain

    Consulting Agreements: Celgene Corporation, Roche Laboratories Inc; Speakers Bureau: Celgene Corporation, Eisai Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

    John Crown, BCh, BAO, BSc, MD, MBA
    Consultant Medical Oncologist
    St Vincent’s University Hospital
    Dublin, Ireland

    Speakers Bureau: Merck, Novartis Pharmaceuticals Corporation; Other Remunerated Activities: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer Inc.

    Angelo Di Leo, MD, PhD
    Head of Sandro Pitigliani Medical Oncology Unit
    Department of Oncology
    Hospital of Prato
    Istituto Toscano Tumori
    Prato, Italy

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech BioOncology; Speakers Bureau: Genomic Health Inc, Sanofi.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Contracted Research: Amgen Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Genomic Health Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genomic Health Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2015
    Expiration date: January 2016

Acknowledge and close

View video: